SCHEMBL1144508

SCHEMBL1144508

CC(=O)c1cc(Br)cc(Cl)c1N

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 5/20 0.40
POLB P06746 1/20 0.38
KDM4E B2RXH2 4/20 0.36
GLA P06280 3/20 0.36
MAOB P27338 2/20 0.36
MAOA P21397 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
HPGD P15428 3/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
NMT1 P30419 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP3A4 P08684 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29947046 1.00 GAA (0.40) GAAMAPTALDH1A1POLBKDM4E
SCHEMBL29664203 0.82 KDM4E (0.46) GAAMAPTALDH1A1KDM4EGLA
SCHEMBL1571554 0.82 KDM4E (0.50) GAAMAPTALDH1A1POLBKDM4E
SCHEMBL20670573 0.82 KDM4E (0.46) GAAMAPTALDH1A1KDM4EGLA
SCHEMBL11626726 0.82 POLB (0.39) GAAMAPTALDH1A1POLBKDM4E
SCHEMBL17376182 0.82 ALDH1A1 (0.40) GAAMAPTALDH1A1POLBKDM4E
Hydrochloric Acid SCHEMBL11626730 0.81 KDM4E (0.48) GAAMAPTALDH1A1POLBKDM4E
SCHEMBL23328071 0.81 ALDH1A1 (0.33) GAAMAPTALDH1A1POLBCA1
SCHEMBL24792656 0.80 GAA (0.49) GAAMAPTALDH1A1POLBKDM4E
SCHEMBL1144686 0.80 ALDH1A1 (0.37) GAAMAPTALDH1A1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747261-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS Accutar Biotechnology Inc. (US) 2026-05-27 EP disclosed
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors ACCUTAR BIOTECHNOLOGY INC. 2025-03-13 US disclosed
WO-2025024388-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2025-01-30 WO disclosed
CN-110655509-B 2-aminopyrimidine derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-01-24 CN disclosed
CN-111094254-B Heteroaryl derivative, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-07-26 CN disclosed
CN-111094254-A Heteroaryl derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2020-05-01 CN disclosed
CN-110655509-A 2-aminopyrimidine derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2020-01-07 CN disclosed
EP-2297163-B1 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-08 EP disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
EP-2297163-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS Pfizer Inc. (US) 2011-03-23 EP disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors CDK6, CDK2, CDK8 GAA 1874/4885MAPT 2517/4885ALDH1A1 3092/4885
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB GAA 587/4885MAPT 1556/4885ALDH1A1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.